Prime Medicine, Inc.
Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company developing genetic medicines using Prime Editing, a gene-editing technology designed to make targeted DNA changes without double-stranded breaks. Its pipeline includes wholly owned in vivo programs for genetic diseases, including PM577 for Wilson disease… From the company’s description.
Over the twelve months to Jun 30, 2026, Prime Medicine, Inc. reported revenue of $4.07M, down 17.9% from a year earlier, and a net loss of $187.89M. Operations used $156.05M in cash. In fiscal 2025, it reported revenue of $4.63M, up 55.3% from fiscal 2024, and a net loss of $201.14M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Prime Medicine, Inc. does
In the company’s own words
Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company developing genetic medicines using Prime Editing, a gene-editing technology designed to make targeted DNA changes without double-stranded breaks. Its pipeline includes wholly owned in vivo programs for genetic diseases, including PM577 for Wilson disease and PM647 for alpha-1 antitrypsin deficiency, as well as an early-stage cystic fibrosis program. Its PM359 ex vivo program is designed to treat chronic granulomatous disease by editing patients’ hematopoietic stem cells; the program has shown restoration of functional protein activity in clinical testing. The company also collaborates with Bristol Myers Squibb on ex vivo T-cell engineering for oncology and immunology applications, and receives support from the Cystic Fibrosis Foundation for its cystic fibrosis work. Prime Medicine’s platform combines engineered Prime Editor enzymes, guide RNAs and delivery systems, including lipid nanoparticles and adeno-associated viruses. Its website is www.primemedicine.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1894562
- SIC
- 2836
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Prime Medicine, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Prime Medicine, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Prime Medicine, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Prime Medicine, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Prime Medicine, Inc.'s last four quarterly filings that the numbers alone won't show?”